RecallRadar

FDA Drug recall D-0619-2018

buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx On…

On 2018-04-11 the FDA classified a Class III recall of buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx On… by Invagen Pharmaceuticals, citing failed Dissolution Specifications; during stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0619-2018
ClassificationClass III
Statusterminated
Initiated2018-03-15
Published2018-04-11
Last updated2026-09-13 11:52 UTC
CompanyInvagen Pharmaceuticals
DistributionUS

Product

buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788

Reason

Failed Dissolution Specifications; during stability testing

Identifiers

ndc69097-877-02
ndc69097-877-03
ndc69097-877-07
ndc69097-877-12
ndc69097-878-02
ndc69097-878-03
ndc69097-878-07
ndc69097-878-12
ndc69097-879-02
ndc69097-879-03
ndc69097-879-07
ndc69097-879-12
code_info
a) Lot I1606609 and Lot I1606610 Exp. Date 05/2018; Lot I1610639 Exp. Date 09/2018 b) Lot #I1606610 Exp Date 05…a) Lot I1606609 and Lot I1606610 Exp. Date 05/2018; Lot I1610639 Exp. Date 09/2018 b) Lot #I1606610 Exp Date 05/2018; Lot I1607847 and Lot I1607845 Exp Date 06/2018; Lot I1610639 Exp Date 09/2018

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0619-2018%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.